Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06VFO
|
||||
| Former ID |
DNAP001613
|
||||
| Drug Name |
Anisodamine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Central and peripheral nervous diseases [ICD10:G96.9] | Approved | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H23NO4
|
||||
| Canonical SMILES |
CN1C2CC(CC1C(C2)O)OC(=O)C(CO)C3=CC=CC=C3
|
||||
| InChI |
1S/C17H23NO4/c1-18-12-7-13(9-15(18)16(20)8-12)22-17(21)14(10-19)11-5-3-2-4-6-11/h2-6,12-16,19-20H,7-10H2,1H3/t12-,13+,14-,15+,16+/m1/s1
|
||||
| InChIKey |
WTQYWNWRJNXDEG-LEOABGAYSA-N
|
||||
| CAS Number |
CAS 55869-99-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Beta-1 adrenergic receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Endocytosis | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Gap junction | |||||
| Salivary secretion | |||||
| Dilated cardiomyopathy | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Beta1 adrenergic receptor signaling pathway | |||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Adrenoceptors | ||||
| G alpha (s) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Endothelin Pathways | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.